Effectiveness and safety of sofosbuvir in treatment-näive children with hepatitis C infection

Journal of the College of Physicians and Surgeons Pakistan

Volumn 27, Issue 7, 2017, Pages 423-426

  Hashmi, Muhammad Almas ^a   Cheema, Huma Arshad ^a  

^a CHILDREN S HOSPITAL   (Pakistan)

Author keywords

Children; Hepatitis C virus; Ribavirin; Sofosbuvir; Treatment n ive

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMBINATION DRUG THERAPY; DRUG SAFETY; DRUG TOLERANCE; EXPERIMENTAL STUDY; FEMALE; GASTROENTEROLOGY; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MALE; OPEN STUDY; PEDIATRIC HOSPITAL; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIROLOGY; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85028512520     PISSN: 1022386X     EISSN: 16817168     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brownell J, Polyak SJ. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 2013; 19:1347-52
2. Khaderi S, Shepherd R, Goss JA, Leung DH. Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation. World J Gastroenterol 2014; 20: 11281-6
3. Islam MS, Miah MR, Roy PK, Rahman O, Siddique AB, Chowdhury J, et al. Genotypes of hepatitis C virus infection in Bangladeshi population. Mymensingh Med J 2015; 24:143-51
4. Tahir A, Malik FR, Ahmad I, Krishin J, Akhtar P. Aetiological factors of chronic liver disease in children. J Ayub Med Coll Abottabad 2011; 23:12-4
5. Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52:827-31
6. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41:1013-8
7. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and metaanalysis. Clin Infect Dis 2013; 56:961-7
8. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140:450-8
9. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010; 34:J322-6
10. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004
11. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22:527-36
12. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44
13. Aziz S, Rajper J, Noorulain W. Treatment outcome of HCV infected paediatric patients and young adults at Karachi, Pakistan. J Ayub Med Coll Abbottabad 2012; 24:56-8
14. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19:7880-8
15. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54:838-55
16. Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. Hamostaseologie 2016; 36 [Epub ahead of print]
17. Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, et. al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat 2017; 24:304-11
18. Mehta R, Kabrawala M, Nandwani S, Tekriwal R, Nandaniya P, Shah M, et. al. Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Indian J Gastroenterol. 2016; 35:459-64
19. Safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection. Available from: https://clinicaltrials.gov/ct2/show/NCT02175758
20. Safety and efficacy of ledipasvir/sofosbuvir fixed dose combination +/-ribavirin in adolescents and children with chronic HCV-infection. Available from: https://clinicaltrials.gov/ct2/ show/study/NCT02249182